Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 1.00 |
| ▸ | PPARD | Q03181 | 20/20 | 1.00 |
| ▸ | PPARA | Q07869 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094544 | 1.00 | PPARG (1.00) | PPARGPPARDPPARA | |
| SCHEMBL5990426 | 1.00 | PPARG (1.00) | PPARGPPARDPPARA | |
| SCHEMBL5990196 | 0.95 | PPARG (0.90) | PPARGPPARDPPARA | |
| SCHEMBL5990191 | 0.95 | PPARG (0.90) | PPARGPPARDPPARA | |
| SCHEMBL5989832 | 0.94 | PPARG (0.88) | PPARGPPARDPPARA | |
| SCHEMBL5989835 | 0.94 | PPARG (0.88) | PPARGPPARDPPARA | |
| SCHEMBL5991771 | 0.94 | PPARG (0.88) | PPARGPPARDPPARA | |
| SCHEMBL5991767 | 0.94 | PPARG (0.88) | PPARGPPARDPPARA | |
| SCHEMBL5989787 | 0.93 | PPARG (0.87) | PPARGPPARDPPARA | |
| SCHEMBL5989781 | 0.93 | PPARG (0.87) | PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007502815-A | — | — | 2007-02-15 | — | — | JP | claimed |
| US-20060257987-A1 | Ppar modulators | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | claimed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | claimed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | claimed |
| US-11241420-B2 | Compositions and methods for prophylaxis and treatment of addictions | OMEROS CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20190022077-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OMEROS CORPORATION | 2019-01-24 | — | — | US | disclosed |
| EP-3398599-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | Omeros Corporation (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10064850-B2 | Compositions and methods for prophylaxis and treatment of addictions | OMEROS CORPORATION (US) | 2018-09-04 | — | — | US | disclosed |
| US-20170027920-A1 | Compositions and Methods for Prophylaxis and Treatment of Addictions | OMEROS CORPORATION | 2017-02-02 | — | — | US | disclosed |
| US-20160331729-A9 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OMEROS CORPORATION (US) | 2016-11-17 | — | — | US | disclosed |
| US-20130296347-A1 | Compositions and Methods for Prophylaxis and Treatment of Addictions | OMEROS CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20100234413-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OMEROS CORPORATION (US) | 2010-09-16 | — | — | US | disclosed |
| US-20060257987-A1 | Ppar modulators | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234413-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OPRK1, OPRL1, PPARA | PPARG 7/4885PPARD 10/4885PPARA 3/4885 |
| US-20160331729-A9 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OPRK1, OPRL1, PPARA | PPARG 7/4885PPARD 10/4885PPARA 3/4885 |
| US-10064850-B2 | Compositions and methods for prophylaxis and treatment of addictions | OPRK1, OPRL1, OPRD1 | PPARG 7/4885PPARD 10/4885PPARA 4/4885 |
| US-20170027920-A1 | Compositions and Methods for Prophylaxis and Treatment of Addictions | OPRK1, OPRL1, PPARA | PPARG 7/4885PPARD 10/4885PPARA 3/4885 |
| US-20190022077-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OPRK1, OPRL1, PPARA | PPARG 7/4885PPARD 10/4885PPARA 3/4885 |
| US-20130296347-A1 | Compositions and Methods for Prophylaxis and Treatment of Addictions | OPRK1, OPRL1, PPARA | PPARG 7/4885PPARD 10/4885PPARA 3/4885 |
| US-11241420-B2 | Compositions and methods for prophylaxis and treatment of addictions | OPRK1, OPRL1, PPARA | PPARG 7/4885PPARD 10/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.